James Parkin, PhD

Dr. Parkin is Senior Scientist and co-founder at Neelyx Labs, a clinical laboratory and diagnostic firm established in 2020 in response to the COVID-19 crisis. Neelyx focuses on fighting the pandemic by bringing cutting-edge science to clinical diagnostics in a timely manner. The high-volume, streamlined lab has performed more than 1M COVID-19 RT-PCR tests to date for the community and facilities like K-12 schools, congregate living, and governments. To date, Neelyx has brought 4 novel clinical diagnostics to life.

Dr. Parkin oversees new diagnostic development and implementation in the clinical laboratory at Neelyx. Most recently, he led the development of a sequencing-based COVID-19 variant diagnostic test, currently under FDA EUA review. Dr. Parkin holds a Ph.D. in Bioengineering from the California Institute of Technology and is notably published in the fields of nucleic acid technologies and microbial systems biology.

Proposed Talk: Democratized clinical variant detection for COVID-19 could enable access to therapeutics in the evolving pandemic